EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

Myung-Ju Ahn, Byoung Chul Cho, Enriqueta Felip, Ippokratis Korantzis, Kadoaki Ohashi, Margarita Majem, Oscar Juan-Vidal iD, Sabin Handzhiev, Hiroki Izumi, Jong-Seok Lee, Rafal Dziadziuszko, Jürgen Wolf und 19 weitere

New England Journal of Medicine · 30.11.2023 · 389 (22) · 2063-2075

DOI: 10.1056/nejmoa2307980 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift New England Journal of Medicine, erschienen am 30.11.2023. Verfasst von Myung-Ju Ahn und 30 weiteren Autor:innen. Beteiligte Einrichtung: From Samsung Medical Center, Sungkyunkwan University School of Medicine (M.-J.A.), and Yonsei Cancer Center, Yonsei University College of Medicine (B…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 635-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Amgen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsSmall Cell Lung CarcinomaAntineoplastic Agents, ImmunologicalHumansAntineoplastic AgentsCytokinesAdministration, IntravenousCytokine Release Syndrome

Substanzen

Antineoplastic AgentsCytokinesAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • From Samsung Medical Center, Sungkyunkwan University School of Medicine (M.-J.A.), and Yonsei Cancer Center, Yonsei University College of Medicine (B.C.C.), Seoul, and Seoul National University Bundang Hospital, Seongna…

ORCID-Profile: Oscar Juan-Vidal

Förderung

  • Amgen

Zitieren

APA

Ahn, M. J., Cho, B. C., Felip, E., Korantzis, I., Ohashi, K., Majem, M., Juan-Vidal, O., Handzhiev, S., Izumi, H., Lee, J. S., Dziadziuszko, R., Wolf, J., Blackhall, F., Reck, M., Bustamante Alvarez, J., Hummel, H. D., Dingemans, A. C., Sands, J., Akamatsu, H., …, & DeLLphi-301 Investigators (2023). Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer. New England Journal of Medicine, 389(22), 2063-2075. https://doi.org/10.1056/nejmoa2307980

Vancouver

Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, et al. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer. New England Journal of Medicine. 2023;389(22):2063-2075. doi:10.1056/nejmoa2307980

BibTeX
@article{Ahn2023,
  author = {Ahn, Myung-Ju and Cho, Byoung Chul and Felip, Enriqueta and Korantzis, Ippokratis and Ohashi, Kadoaki and Majem, Margarita and Juan-Vidal, Oscar and Handzhiev, Sabin and Izumi, Hiroki and Lee, Jong-Seok and Dziadziuszko, Rafal and Wolf, Jürgen and Blackhall, Fiona and Reck, Martin and Bustamante Alvarez, Jean and Hummel, Horst-Dieter and Dingemans, Anne-Marie C and Sands, Jacob and Akamatsu, Hiroaki and Owonikoko, Taofeek K and Ramalingam, Suresh S and Borghaei, Hossein and Johnson, Melissa L and Huang, Shuang and Mukherjee, Sujoy and Minocha, Mukul and Jiang, Tony and Martinez, Pablo and Anderson, Erik S and Paz-Ares, Luis and DeLLphi-301 Investigators, DeLLphi-301 Investigators},
  title = {Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {389},
  number = {22},
  pages = {2063--2075},
  doi = {10.1056/nejmoa2307980}
}
Kostenlos starten →